News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Altus Pharmaceuticals Inc. (ALTU) Secures Long-Term Growth Hormone Supply For ALTU-238 Clinical Development and Commercialization



7/10/2008 10:19:04 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a biopharmaceutical company focused on oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders, announced today that it signed a long-term agreement to purchase recombinant human growth hormone (rhGH) for ALTU-238 for development and commercialization. Altus is developing ALTU-238 as a subcutaneously administered, long-acting formulation of rhGH that employs the Company’s proprietary protein crystallization and formulation technology.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES